RLS affects around 7% of people, with symptoms worsening at night due to dopamine fluctuations, and while there’s no cure, lifestyle changes, medications, and treating underlying conditions can help manage it.
Rising deaths from pregabalin, also used for restless legs syndrome, spotlight the need for drug interaction knowledge to protect patients.
The International Restless Legs Syndrome Study Group published consensus guidelines on rodent models of RLS.
The 2022 CDC Opioid Prescribing Guidelines released on November 3, 2022, replaced earlier guidelines that had led to confusion, misinterpretation, and faulty application by medical providers, according to a statement from the RLS Foundation.
Read More
The International Restless Legs Syndrome Study Group publishes a new guideline on construct validity of rodent models of RLS.
Read More
A new study found Pycnogenol French maritime pine bark extract to significantly relieve and prevent symptoms associated with restless legs syndrome.
Read More
In ODYSSEY II, 2,745 people with confirmed RLS completed a survey about RLS diagnosis and severity, associated medical conditions, treatments, and medical care.
Read More
Twenty percent of restless legs syndrome patients are already on higher-than-recommended doses of dopamine agonists, says John Winkelman, MD, PhD.
Read More
The acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read More
Ben Wipper discusses the study “Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic.”
Read MoreA patient writes into the Mayo Clinic News Network to ask if their child might be experiencing restless legs syndrome.
Read More
The Restless Legs Syndrome Foundation updates its algorithm for the management of RLS. The most notable change is a firm pivot away from dopamine agonist medications as first-line treatments.
Read MoreA writer for Popular Science reviews ways to cope with having a bed partner with restless legs syndrome.
Read MoreThe Restless Legs Syndrome (RLS) Foundation is hosting a free webinar Wednesday on “SIBO, Diet and RLS” with Leonard Weinstock, MD.
Read MoreAzurity Pharmaceuticals Inc has acquired Arbor Pharmaceuticals Inc, marketers of the restless legs syndrome drug Horizant.
Read More
In a transcriptome-wide study, researchers pinpoint PPP3R1 and other novel genetic risk factors of interest in RLS.
Read More
A new treatment reduces motor and sensory symptoms of restless legs syndrome (RLS) and improves sleep duration.
Read MoreRestless sleep is an umbrella term for a varied range of behaviors people experience while sleeping, and that prevent them from getting proper rest at night, including restless legs syndrome.
Read More